Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Hepatitis C × Lymphoid × Clear all

Phase

Phase 4 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2 Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 55 Lymphoma 33 Lymphoma, Follicular 28 Lymphoma, Non-Hodgkin 25 Leukemia, Lymphocytic, Chronic, B-Cell 15 Recurrence 11 Leukemia 11 Lymphoma, Large B-Cell, Diffuse 10 Lymphoma, B-Cell 10 Lymphoma, T-Cell, Cutaneous 8 Waldenstrom Macroglobulinemia 7 Hodgkin Disease 6 Neoplasm, Residual 5 Mycosis Fungoides 5 Lymphoma, T-Cell, Peripheral 5 Lymphoma, T-Cell 5 Febrile Neutropenia 5 Asthma 5 Pain 4 Neoplasms 4 Multiple Myeloma 4 Lymphoma, Mantle-Cell 4 Leukemia, Myeloid, Acute 4 Hematologic Diseases 4 Burkitt Lymphoma 4 Sezary Syndrome 3 Neoplasms, Plasma Cell 3 Myelodysplastic Syndromes 3 Lymphoma, Large-Cell, Anaplastic 3 Lymphoma, B-Cell, Marginal Zone 3

Interventions

ledipasvir, sofosbuvir drug combination 1 Sofosbuvir 1 Ribavirin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02717949 2019-01-08

Optimal

University of Texas Southwestern Medical Center

Phase 4 Terminated

Hepatitis C, Liver Diseases, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon ⚡